CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-02 | Galletta Christopher See Remarks | Option exercise · Stock Option (right to buy) | −4,225 | 15,775 | ||
| 2025-06-11 | Mathers Edward T Director | Grant or award · Nonstatutory Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-06-11 | Colangelo Dominick Director | Grant or award · Nonstatutory Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-06-11 | Heffernan Michael Thomas Director | Grant or award · Nonstatutory Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-06-11 | VANLENT ANNE Director | Grant or award · Nonstatutory Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-06-11 | Meeker David P Director | Grant or award · Nonstatutory Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-05-31 | Galletta Christopher See Remarks | Grant or award · Performance Stock Option (right to buy) | +8,550 | 13,110 | ||
| 2025-05-31 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Performance Stock Option (right to buy) | +60,000 | 92,000 | ||
| 2025-05-31 | Delfini Lisa Chief Financial Officer | Grant or award · Performance Stock Option (right to buy) | +72,000 | 110,400 | ||
| 2025-05-31 | Simon Farrell Chief Commercial Officer | Grant or award · Performance Stock Option (right to buy) | +72,000 | 110,400 | ||
| 2025-05-31 | GOOD JENNIFER L President & CEO | Grant or award · Performance Stock Option (right to buy) | +102,000 | 156,400 | ||
| 2025-03-25 | SCIASCIA THOMAS Chief Scientific Officer | Option exercise | +2,631 | $1.43 | $4K | 224,004 |
| 2025-03-25 | SCIASCIA THOMAS Chief Scientific Officer | Sale | −2,631 | $6.60 | $17K | 221,373 |
| 2025-03-25 | SCIASCIA THOMAS Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −2,631 | 0 | ||
| 2025-03-21 | GOOD JENNIFER L President & CEO | Option exercise | +5,263 | $1.43 | $8K | 218,576 |
| 2025-03-21 | GOOD JENNIFER L President & CEO | Sale | −5,263 | $6.58 | $35K | 213,313 |
| 2025-03-21 | GOOD JENNIFER L President & CEO | Option exercise · Stock Option (right to buy) | −5,263 | 0 | ||
| 2025-03-10 | GOOD JENNIFER L President & CEO | Grant or award · Performance Stock Option (right to buy) | +54,400 | 54,400 | ||
| 2025-03-10 | Delfini Lisa Chief Financial Officer | Grant or award · Performance Stock Option (right to buy) | +38,400 | 38,400 | ||
| 2025-03-10 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Performance Stock Option (right to buy) | +32,000 | 32,000 |
Page 2 of 9 · 179 trades